Complesys(Biopulse)-Krebstest mit großer Zukunft - 500 Beiträge pro Seite

[Bombenleger]

Wer interssiert sich noch für die Firma Biopulse.
Zuzeit sind 3 Krebstests in der Entwicklung.
Hier ein kurzer Überblick.
Welcome To The
Complesys Website
Many biotech companies are focusing in immune-based therapy for cancer and other diseases.
Complesys is participating in these efforts by licensing technology in the field and developing
integrated cancer treatment programs. The Complesys "integrated medicine" approach includes
elements of both biotech research and alternative medicine.

We believe that an effective program to control and effectively treat cancer must include three
elements:

Prevention
Early Detection
Holistic Treatment



Complesys believes that we have leading technology in the following areas:

anti-angiogenesis agents
cancer vaccine preparation
cancer diagnostics
immune stimulants
tumor antigen isolation
cytokine-based treatments

Der Kurs hatte leider sehr sehr gelitten.Ein Grund dafür war unter anderem falsche Gerüchte.
Die Firma beschäftigt sich mit alternativen Medizin.Ein bereich der meiner Meinung nach
etwas vernachlässigt wird.
Für weitere Fragen stehe ich gerne zur verfügung oder die Homepage www.complesys.com

[Bombenleger]

BioPulse International, Inc. is in the business of managing integrated
medicine clinics and medical research programs. The Company offers a
variety of alternative medicinal products and services, including dietary
supplements, clinical procedures, and medical equipment from around the
world. The Company`s efforts focus on treatments for degenerative
diseases such as cancer.

[Bombenleger]

Comprehensive Cancer
Care
October 19-21, 2001
Hyatt Regency Crystal Ctiy
Arlington, VA
Whole Life Conference
October 19-21, 2001
Los Angeles Convention
Center Los Angeles, CA
Immuno-Supportive
Cancer Care
Dr. Schramm and Dr.
Kim O’Neill will be
featured speakers
Nov. 4, 2001(9:00 to
5:00)
Philidelphia (Thomas Jefferson
University Medical Center)
ACAM
(American College for
Advancement in
Medicine)
November 14-18,
2001
Long Beach, CA
Whole Life Conference
November 16-18,
2001
McCormick Place Chicago, IL
Anti-Aging Conf. &
Expo
December 14-16, 2001
Las Vegas, NV
12th International Conf.
On Pharmaceutical
Medicine
May 5-8, 2002
Cancun, Mexico
AHMA (Holistic
Medicine Scientific
Conf)
May 15-18, 2002
The Hilton Toronto Hotel
Toronto, Canada
American Society for
Microbiology Gen Mtg.
May 20-22, 2002
Salt Palace
Salt Lake City, Utah

[Die Stimme]

ICH SITZ AUCH NOCH AUF DIESER LEICHE; AU?ER NACH UNTEN HAT SICH DA BISHER NIX GETAN
SCHADE EIGENTLICH; ABER NACHDEM ICH DERZEIT EH ZUVIEL GLÜCK HABE
EXODUS -87% UND BVSN-82% stört mich die 79% minus auch schon nicht mehr

schade biopulse, aber ich glaube an meine geduld

[Bombenleger]

@ Die Stimme,

Geduld zahlt sich aus.

BioPulse Technologie zur Krebsdiagnostik erhaelt gute fachliche Beurteilung

Cancer Detection and Prevention publiziert erste Forschungsergebnisse in Bezug auf einzigartigen
Immuntest

San Ysidro, Kalifornien (ots-PRNewswire) - BioPulse International, Inc., (OTC Bulletin Board: BIOP;
Frankfurt: BPZ) gab heute die Veröffentlichung von Untersuchungsergebnissen in der Zeitschrift Journal
of Cancer Detection and Prevention bekannt, dem offiziellen Organ der International Society for
Preventive Oncology (ISPO). Die von Kim L. O`Neill, Ph.D, und Kollegen an der Brigham Young
University verfasste Studie stellt Ergebnisse in Bezug auf den Thymidinkinase I Immuntest (TK1) dar: ein
potenzieller neuer Brustkrebsmarker.

Loran Swensen, Präsident von BioPulse kommentierte, "BioPulse and Covance, Inc. entwickeln derzeit die
Markteinführung dieser Technologie für einen späteren Zeitpunkt dieses Jahres. Die weltweiten
Marktumsätze werden auf 28 Milliarden US$ geschätzt. Die Technologie ist derzeit durch ein
Schlüsselpatent geschützt, das noch für etwa 15 Jahre gültig ist. Der Testkit ist zum frühen Nachweis von
Krebs gedacht, sowie für die Beobachtung des Verlaufes der Krebsbehandlung und der Entwicklung einer
Prognose für den Patienten nach der Behandlung. Der Test gilt als Durchbruch in der Forschung. Seine
Einfachheit, die niedrigen Kosten, die hohe Genauigkeit, die Tatsache, dass es sich um einen
nicht-invasiven Test handelt und die Möglichkeit der Frühentdeckung sind bei den meisten
Erkrankungsfällen entscheidende Vorteile gegenüber den anderen Bluttests, Radiogrammen, Biopsien,
etc."

Auszüge aus dem Artikel in der Zeitschrift Cancer Detection and Prevention:

Die Studie die unter der Leitung von Kim L. O`Neill Ph.D durchgeführt wurde, umfasst die Quantifizierung
der TK1-Aktivität mit Hilfe des Strahlentests und der Proteinmengen mit Hilfe unseres monoklonalen
Antikörpers in 218 Serumproben von Fällen postoperativen Brustkrebses. Es ergab sich eine Korrelation
der beiden Tests. Unsere Ergebnisse zeigten, dass der TK1 Immuntest-Antikörper nicht nur eine lineare,
reproduzierbare und spezifische Antwort ergab, sondern die Menge an TK1 in Brustkrebszellen und im
Serum genau misst. Unser monoklonaler Antikörper ist beim Management von Brustkrebs möglicherweise
von klinischem Nutzen.

Die TK1-Aktivität wird derzeit mit Hilfe eines nicht sehr empfindlichen Strahlentests gemessen, der in den
50er Jahren entwickelt worden war. Frühere Forschungsergebnisse ließen vermuten, dass TK1 als
diagnostisches Werkzeug verwendbar ist und den Kliniker bei der Erstellung der Prognose und Diagnose
von Brustkrebs unterstützen kann. Rückschläge bei der Verwendung dieses Strahlentests waren
allerdings der Grund für Frustration bei den klinischen Anwendern. Aus diesem Grund haben wir einen
monoklonalen Antikörper gegen TK1 entwickelt. Dessen Zuverlässigkeit wurde mittels der ELISA
Technologie geprüft. Eine Erhöhung der TK 1-Aktivität liegt nicht nur bei Patienten im fortgeschrittenen
Stadium vor, sondern auch bei Patienten mit Primärtumor. Dies ist bei anderen Tumormarkern nicht der
Fall. Mittels einer wiederholten Messung der TK1-Aktivität im Serum lassen sich Rückfälle und
Remissionen verfolgen; das Maß der TK1-Aktivität in primären Brustgewebstumoren korreliert in direkter
Weise mit einer Wiederkehr des Tumors.

Über BioPulse:

Dieses schnell wachsende und profitable Unternehmen der Biotechnologiebranche hat seinen Hauptsitz
in San Diego und kombiniert alternative mit biotechnologischen Behandlungsweisen für Krebs und
andere Erkrankungen. Das Unternehmen verfügt über ein beeindruckendes Portfolio patentierter
Therapeutika und Diagnostika, die außerhalb der USA in klinischen Studien getestet werden. Die
teilnehmenden Kliniken bieten eine Reihe der modernsten medizinischen Verfahren an.

Über Cancer Detection and Prevention:

Die Zeitschrift Cancer Detection and Prevention ist das offizielle Organ der International Society for
Preventive Oncology (ISPO), einer nicht-staatlichen Organisation, die in offizieller Verbindung mit der
Weltgesundheitsorganisation steht. Die Zeitschrift gibt den Standpunkt der Organisation wieder, dass es
sich bei Krebs um eine vermeidbare Erkrankung handelt und dass die Nutzung des Gesamtwissens die
Morbidität und Mortalität von Patienten mit neoplastischen Erkrankungen eliminieren könnte.

Diese Pressemitteilung enthält in die Zukunft gerichtete Aussagen im Sinne der "Safe
Harbor"-Bestimmungen der US-Securities and Exchange Commission im Rahmen des Private Securities
Litigation Reform Act aus dem Jahre 1995 und Regelung 3b-6 des Securities Exchange Act aus dem Jahre
1934. Diese beinhalten Risiken und Unwägbarkeiten, die dazu führen könnten, dass die tatsächlichen
Ergebnisse erheblich von den Erwartungen des Unternehmens abweichen.

Originaltext: BioPulse International, Inc.

[Bombenleger]

@ Die Stimme,

es gibt keinen Grund zum pessimissmus.Alles läuft nach Plan.
Es gibt bisher keine schlechten Ergebnisse beim TK-1 Test.
Die Firma hat bereits vor Monaten darauf hingewiesen das es
mindestens Ende 2001 wird bis der Test anläuft.
Sollte er auf den Markt kommen bzw.alle 3 ist der Test schon aufgrund
des günstigen Preises konkurrenzlos.
Also noch ein paar Monate Geduld.

[Bombenleger]

Key holders of BioPulse file to sell


By Penni Crabtree
STAFF WRITER

October 31, 2001


Amid new warnings about financial problems, major shareholders in the
company that operates a controversial Tijuana clinic told federal regulators
they may try to sell a large portion of their holdings.

BioPulse International, which has offices in Chula Vista, filed a registration
statement late Friday with the Securities and Exchange Commission on
behalf of 11 shareholders who propose to sell 45 million shares "as soon as
practicable from time to time."

The shareholders, not the company, will receive proceeds if the sales
occur. BioPulse`s over-the-counter stock, which traded for as much as $12
in December, closed yesterday at 13 cents.

The proposed stock sale comes at a difficult time for the company, whose
unproven alternative cancer treatments drew the attention of U.S. and
Mexican authorities earlier this year.

In February, Baja California health officials ordered BioPulse to cease
providing desperately ill cancer patients with some alternative therapies,
including insulin-induced comas and cancer "vaccines" derived from
human urine.

Baja authorities said BioPulse had not filed for permits to provide
alternative therapies or conduct experimental research on patients. Many
in the established medical community dismiss the treatments as ineffective
and dangerous.

BioPulse also learned in February that the Federal Trade Commission had
started an inquiry into its advertising practices -- including whether it
could prove the claims of success it made for its treatments.

Since then, BioPulse`s stock has lost most of its value and the clinic --
which provides 90 percent of BioPulse`s revenue -- most of its patients.

In its SEC filing, BioPulse offered a bleak picture for potential investors.
The company said it has reduced its staff to officers and directors "whom
we are not able to pay on a regular basis," and that BioPulse is "having
difficulty generating revenues."

Revenue for the quarter ended April 30, the last period that BioPulse
reported, was $265,360, compared with $1.1 million the same period a year
ago.

The regulatory climate in Mexico and uncertainty about the future of its
therapies and products "raises a substantial possibility of our being
unable to continue as a going concern," according to the filing.

Under Mexican law, the only way a clinic can offer many alternative
therapies is through a research license granted by Mexico`s federal health
department. The clinics must submit a detailed protocol detailing their
investigation, and they can`t charge patients to take part in the research
studies.

But corruption and a laissez-faire attitude toward enforcing the law have
allowed alternative clinics to operate for decades. Only recently have
Mexico`s health officials cracked down on illegal clinics, forcing them to
seek research permits or face closure.

In BioPulse`s SEC filing, it outlined some business strategies that still
appear to contradict Mexico`s health-care regulations -- posing a potential
for new problems.

BioPulse said in its filing that it was notified Oct. 17 that Mexican
authorities had approved licenses that allow the company to treat patients
with three alternative therapies, including a controversial insulin treatment.
A fourth license, to provide cancer vaccines, was approved provisionally,
pending a six-month review, the company said.

The company also said in its filing that it will charge patients "on a
fee-for-service" basis to take part in BioPulse`s "clinical studies" in
Tijuana.

BioPulse officials did not return telephone calls.

Dr. Alfredo Gruel Culebro, who oversees clinics and hospitals for the Baja
California Health Department, said yesterday that BioPulse has not yet
been approved for any license to provide alternative therapies.

He said the company will likely win permission to offer chelation therapy
and enemas, the latter because "while not effective, it isn`t considered very
dangerous," Gruel said.

Gruel said BioPulse requested a license to use insulin in conjunction with
chemotherapy, but not in a way intended to induce a coma, Gruel said. If
the protocol for the study is approved, BioPulse will not be allowed to
charge patients for it, he said.

A license to offer cancer vaccines also has not been approved, nor can the
company charge patients for it, Gruel said.

"If it is proven that they are charging patients, the protocol will be
suspended," said Gruel.

[Bombenleger]

December 21, 2001

BIOPULSE INTERNATIONAL INC/ (BIOP.OB)

Quarterly Report (SEC form 10QSB)

ITEM 2 MANAGEMENTS DISCUSSION AND ANALYSIS

Management`s Discussion and Analysis

The following discussion contains comments about the financial condition of BioPulse International, Inc. for the Quarter Ended October 31, 2001.

Overview

Since inception in January 1999, we have been refining our operations and developing our market. We have advertised in periodicals targeting potential patients, rented
booths at trade shows, and sought to develop a good reputation through positive results and satisfied patients. We have introduced new treatments for our patients and
expanded our market.

From January 1999 we have managed Clinica BioPulso in Tijuana, Mexico, through a management contract with a physician licensed in Mexico. We were entitled to all
revenues and are responsible for all expenses of the clinic. More than 90% of our operating revenues and expenses and profits were generated by the Mexican
operations.

During 2001, the Mexican government revamped its oversight of medical clinics subject to its jurisdiction. It sent new health department inspectors to review the
operations and permits of many clinics in Tijuana, Mexico. This led to the closure of several clinics there. Clinica BioPulso also was inspected. The inspectors determined
that while the clinic personnel were properly qualified, they had not submitted all of their protocols for government review. On February 15, 2001, one treatment room
was closed pending review of the protocols. The clinic submitted applications for licenses for four protocols (insulin hypoglycemic therapy, chelation, colonic treatments,
and dendrytic cell therapies) in May 2001. On May 9, 2001, the Instituto de Servicios de Salud Publica Del Estado De Baja California (the Mexican health authorities)
reopened the treatment room. As a result of the new policy, the clinic decided not to seek new patients until all the necessary protocols had been approved. Approval of
these permits are still pending.

Prior acquiring TK-1 technology in December, 2000, we have not incurred material research and development expenses outside of the treatment of patients at the clinic
in Tijuana, Mexico. We conducted research and development using data from records of the patients treated at the clinic in Mexico to determine the effectiveness of the
treatments. Additionally, we are working with the doctors who are modifying the treatments based on the data received from the treatment of patients. This limited
research and development has been integrated into the patient care given to paying patients, and we have not had any material research and development costs to date
that were distinguishable from patient care. All costs of patient care have been expensed in the period in which they were incurred. We paid $100,000 for the TK-1
technology that is not refundable should we not be able to develop a marketable product. This $100,000 has been expenses as research and development expenses plus
the costs incurred to develop TK-1 into a marketable product.

During 2000, we had an outpatient clinic at our office in Utah. The revenues and expenses generated by this clinic were not material, and the clinic no longer has any
ongoing patient care operations.

Revenues

The clinic produced almost no revenue during the quarter ended October 31, 2001, down from 1,569,680 from clinic operations for same period last year. This is due to
our not accepting new cancer patients after being informed that we need additional permits from the Mexican government to offer the treatments that had bee previously
offered as discussed above.

Costs and Expenses

Cost of sales was $4,773 for the quarter ended October 31, 2001 down from $398,359 from the same period last year. This is due to the almost total loss of patients at
the clinic. General and Administrative expenses were $628,600 for the quarter ended October 31, 2001 down from $679,803 for the same period last year. Most of the
general and administrative expenses are fixed costs that are not controllable in the short run. One primary fixed cost is rent of the clinic in Tijuana, Mexico. The clinic
rent is $42,000 per month and $329,000 is due as of October 31, 2001 and is included in accounts payable. The landlord is working with us to resume operations and it is
in his best interest to not evict us. The lease was renegotiated in February 2001. Prior to the renegotiation, rent was charged on patient rooms as they were used and
were a cost of sales. After the renegotiation, rent on the whole facility was charged as a fixed amount regardless of occupancy; thus rent on patient rooms became a
fixed or general and administrative expense. The fixed rent increased $ 31,000 per month in February 2001. Staff salaries were reduced in the quarter ended October 31,
2001 by approximately 50,000 over the same period in the prior year.

Significant Elements of Income or Loss That Do Not Arise From Continuing Operations

There were no significant elements of income or loss that do not arise from continuing operations.

Liquidity

As of October 31, 2001, the Company had current assets of $327,238 and current liabilities of $1,083,064. Clinic operations had been generating near breakeven cash
flow through January 2001 but due to the change in the regulatory

climate in Mexico and resulting decrease in the number of patients that have been treated at the clinic, the clinic has generated net negative cash flow since January
2001. We have used most of our cash resources as of October 31, 2001 and have laid off most of our administrative personnel and the Mexican clinic has laid off most
of it personnel until operations resume. The officers have continued to work and their salaries have accrued but have not been paid during October and November. As of
October 31, 2001, we have approximately $250,000 in cash in escrow with Brigham Young University and expect to be able to access $150,000 of that. That would leave
more than enough to pay for the expected costs to complete development of the TK-1 diagnostic test. As of October 1, 2001 we are in default on our loan of $500,000
with Hunts Drive Ltd. That loan was secured by the 2,093,400 shares of stock owned by Loran Swensen and Johathan Neville, Officers and Directors of the company.
We expect to be able to reopen the clinic in Tijuana under a new agreement with the doctors where they would use our equipment and facility and would pay us a flat
fee for that and consulting services

We believe that cash flow from the operations of the Clinica BioPulso in Tijuana, Mexico, will be positive in the foreseeable future.

Seasonal Aspects

We have experienced lower patient occupancy during late fall and early winter months than during other times of the year. Although there may be other reasons for this,
our treatments are elective treatments, and typically, patients may choose to not seek these treatments during holiday seasons, preferring instead to seek treatment at
other times of the year.

Material Commitments for Capital Expenditures and Capital Resources

There are no material commitments for capital expenditures. BioPulse has committed to develop the ELISA kit for the TK-1 diagnostic technology that was acquired
from Brigham Young University. This is expected to cost less than $50,000.

[Bombenleger]

Income Statement

Balance Sheet

Cash Flow Statement



Period Ending:
Oct 31, 2001
Jul 31, 2001
Apr 30, 2001
Jan 31, 2001
Total Revenue
$20,001
$8,393
$265,360
$703,241
Cost Of Revenue
$4,773
$45,812
$117,682
$298,137
Gross Profit
$15,228
($37,419)
$147,678
$405,104
Operating Expenses
Research And Development
$20,000
$210,438
N/A
N/A
Selling General And Administrative Expenses
$628,600
($563,776)
$1,453,792
$5,481,987
Non Recurring
N/A
N/A
N/A
N/A
Other Operating Expenses
N/A
N/A
N/A
N/A
Operating Income
($633,372)
$315,919
($1,306,114)
($5,076,883)
Total Other Income And Expenses Net
N/A
N/A
N/A
N/A
Earnings Before Interest And Taxes
($633,372)
$315,919
($1,306,114)
($5,076,883)
Interest Expense
N/A
N/A
N/A
N/A
Income Before Tax
($633,372)
$315,919
($1,306,114)
($5,076,883)
Income Tax Expense
N/A
N/A
N/A
N/A
Equity Earnings Or Loss Unconsolidated Subsidiary
N/A
N/A
N/A
N/A
Minority Interest
N/A
N/A
N/A
N/A
Net Income From Continuing Operations
($633,372)
$315,919
($1,306,114)
($5,076,883)
Nonrecurring Events
Discontinued Operations
N/A
N/A
N/A
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
Effect Of Accounting Changes
N/A
N/A
N/A
N/A
Other Items
N/A
N/A
N/A
N/A
Net Income
($633,372)
$315,919
($1,306,114)
($5,076,883)
Preferred Stock And Other Adjustments
N/A
N/A
N/A
N/A
Net Income Applicable To Common Shares
($633,372)
$315,919
($1,306,114)
($5,076,883)

More filings for BioPulse International Inc available from EDGAR 0nline. Get a Free Trial to EDGAR Online Premium
EDGAR Online: Research People in this company | Full text Search
ADVERTISEMENT

[Bombenleger]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

Quarterly Report Under Section 13 or 15(d)
of the Securities and Exchange Act of 1934

For the Quarter Ended: Commission File Number
---------------------- ----------------------
October 31, 2001 0-28973
0-28973

BioPulse International, Inc.
-----------------------------
(Name of small business issuer in its chapter)

Nevada 87-0634278
---------------------------------- ------------------------------------
(State or other jurisdiction of (I.R.S. Employer I.D. No.)
incorporation or organization)

10421 South Jordan Gateway, Suite 500, South Jordan, Utah 84095
--------------------------------------------------------- ------------
(Address of principal executive offices) (Zip Code)

Issuer`s telephone number, including area code [phone]
----------------------



Securities registered pursuant to section 12(b) of the Exchange Act: None

Check whether the Issuer (1) filed all reports required to be filed by section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that
the registrant was required to file such report(s), and (2) has been subject to such filing requirements for the past 90 days. (1) Yes [X ] No [ ]

State the number of shares outstanding of each of the registrants classes of common equity, as of the latest practicable date:

As of October 31, 2001, issuer had approximately 10,926,746 shares of its $.001 par value common stock outstanding.

1



PART I FINANCIAL INFORMATION


ITEM 1 FINANCIAL STATEMENTS


Pages F-3 through F-13 will directly follow.

Consolidated Balance Sheet as of October 31, 2001
and October 31, 1999 F-2

Consolidated Statement of Operations for the three
months ended October 31, 2001 and 2000 F-3

Consolidated Statement of Cash Flows for the three
months ended October 31, 2001 and 2000 F-4

Notes to Financial Statements F-5




F-1

Biopulse International, Inc.
Consolidated Balance Sheet


Assets
October 31, October 31,
2001 2000
----------- -----------
Current Assets
Cash $ 7,631 $ 104,189
Escrow Account 255,280
Accounts receivable (net of allowance for -- 112,940
doubtful accounts)
Inventory 64,327 83,502
Note Receivable - Employee -- 9,800
Note Receivable -- 19,032
Prepaid Rent , Current -- 135,080
----------- -----------
Total Current Assets 327,238 464,543
----------- -----------

Property & Equipment, Net (Note 2) 1,235,023 848,238
Intangable Assets 637,500 689,706

Other Assets
Deposits 8,731 8,731
Prepaid Rent - Net of Current Portion -- 151,594
----------- -----------
Total Other Assets 8,731 160,325
----------- -----------
Total Assets $ 2,208,492 $ 2,162,812
=========== ===========




Liabilities and Stockholders` Equity

Current Liabilities
Accounts Payable $ 502,064 $ 92,739
Accrued Expenses 81,000 20,081
Notes Payable 500,000 911,600
Unearned Revenue -- 30,466
----------- -----------
Total Current Liabliities 1,083,064 1,054,886
----------- -----------
Total Liabilities 1,083,064 1,054,886
----------- -----------

Stockholders Equity
Preferred Stock 3,000,000 --
Common Stock 10,927 7,464
Additional Paid in Capital 4,925,386 1,226,934
Less Subscriptions Receivable (99,266) (119,586)
Treasury Stock (4,283) --
Accumulated Deficit (6,707,336) (6,886)
----------- -----------
Total Stockholders` Equity 1,125,428 1,107,926
----------- -----------
Total Liabilities and Stockholders` Equity $ 2,208,492 $ 2,162,812
=========== ===========




See Notes to the Consolidated Financial Statements

F-2

Biopulse International, Inc.
Consolidated Statement of Operations


For the Three For the Three
Months Ended Months Ended
October 31,2001 October 31, 2000
------------ ------------
Revenues $ 20,001 $ 1,159,680
Cost of Sales 4,773 398,359
------------ ------------
Gross Profit 15,228 761,321
------------ ------------
Operating Expenses

General and Administrative 628,600 679,803
Research & Development 20,000 --
------------ ------------
Total Expenses 648,600 679,803
------------ ------------
Net Profit (Loss) From Operations (633,372) 81,518

Net Income (Loss) before taxes (633,372) 81,518

Provision for Income taxes
------------ ------------
Net Income (Loss) $ (633,372) $ 81,518
============ ============

Net Income Per Share $ (0.06) $ 0.01

Weighted average Shares Outstanding 10,926,746 7,464,110

Fully diluted earnings per share $ (0.01) $ 0.01

Fully diluted weighted-average shares outstanding 72,026,364 8,626,443




See Notes to the Consolidated Financial Statements

F-3

Biopulse International, Inc.
Consolidated Statement of Cash Flows

For The Three For The Three
Months Ended Months Ended
October 31, 2001 October 31, 2000
--------- ---------
Cash flows from operating activities

Net Income $(633,372) $ 81,518
Adjustment to reconcile net income
to cash provided by operations
Depreciation and Amortization 58,616 42,144
(Increase) decrease in receivables -- (95,910)
(Increase) decrease in Inventory 4,773 (6,408)
(Increase) decrease in Prepaid rent -- 30,000
Increase (decrease) in payables 220,259 (12,048)
Increase (decrease) in credit card debt (51,737) --
Increase (decrease) in accrued expenses 60,513 (10,065)
Increase (decrease) in unearned fees (47,318)
--------- ---------
Net cash provided by operating activities (340,948) (18,087)
--------- ---------


Cash flows from investment activities
Purchase of Equipment -- (160,379)
Acquisition of Intangable assets -- (700,000)
--------- ---------
Net Cash (used) provided by investing activities -- (860,379)
--------- ---------

Cash flows from Financing Activities
Issued common stock for cash -- 75,000
Increase (decrease) in short-term debt -- 825,600
(Increase) decreace in subscription receivable -- 40,000
--------- ---------
Net cash (used) provided by financing activities -- 940,600
--------- ---------

Net increase (decrease) in cash (340,948) 62,134

Cash, beginning of period 603,859 42,055
--------- ---------
Cash, end of period $ 262,911 $ 104,189
========= =========




See Notes to the Consolidated Financial Statements

F-4

Biopulse International, Inc.
Notes to the Financial Statements
October 31, 2001 and October 31, 2000

NOTE 1 - Summary of Significant Accounting Policies

a. Organization

Biopulse International, Inc. (BioPulse) was incorporated in the State of Nevada on July 13,1984 originally under the name of Universal Financial Capital Corp (UFC).
UFC changed its name in September 1985 to International Sensor Technologies, Inc.(IST). IST incurred heavy losses and no revenue from operations and thereafter
experienced five years of inactivity. On January 12, 1999, IST changed its name to BioPulse International, Inc. when it acquired BioPulse, Inc. BioPulse is in the
business of managing integrated medical clinics, and medical research programs.

BioPulse issued 4,000,000 common shares in exchange for 100 percent of the outstanding stock of Biopulse Inc., a Utah corporation organized June 4, 1998. The share
exchange with Biopulse, Inc. was accounted for as a reverse acquisition (recapitalization), therefore all historical financial information is that of the accounting survivor
Biopulse, Inc.

The Company also paid $100,000 to an officer/director of the Company for accounting, legal and organization expenses to recapitalize the Company. This was recorded
as general and administrative expense during the year ended July 31, 1999.

b. Recognition of Revenue

The Company recognizes income and expense on the accrual basis of accounting. Patients are generally charged a flat fee for treatment for a specified period of time
and recorded as unearned revenue. Revenue from services to patients is recognized as services are performed. Patients who do not complete the entire treatment
schedule are refunded fees prorated on a daily basis.

Patient recruitment fees, consulting fees and provision of equipment for other non-affiliated clinics are recognized as revenue when services have been rendered,
equipment installed and no right of return of fees exists.

c. Earnings (Loss) Per Share

The computation of earnings per share of common stock is based on the weighted average number of shares outstanding at the date of the financial statements.

d. Cash and Cash Equivalents

BioPulse considers all highly liquid investments with maturities of three months or less to be cash equivalents.

F-5

Biopulse International, Inc.
Notes to the Financial Statements
October 31, 2001 and October 31, 2000

NOTE 1 - Summary of Significant Accounting Policies (continued)

e. Provision for Income Taxes

No provision for income taxes has been recorded due to net operating loss carryforwards totaling approximately 6,000,000 that will be offset against future taxable
income pursuant to limitations of the Internal Revenue Code. These NOL carryforwards begin to expire in the year 2000. No tax benefit has been reported in the
financial statements because BioPulse believes there is a 50% or greater chance the carryforward will expire unused, and are limited pursuant to the Internal Revenue
Code. The loss from the year ended July 31, 1999 can be used to offset income for the period ended October 31, 2000. Accordingly, no tax provision has been recorded.

Deferred tax assets and the valuation account is as follows at October 31, 2001 and October 31, 2000:

October 31, 2001 October 31, 2000
----------------------------------------------------------- ------------------
Deferred tax asset:
NOL carrryforward $ 2,000,000 $ 700,000
Valuation allowance (2,000,000) (700,000)
------------------ ------------------

Total $ - $ -
================== ==================




f. Principles of Consolidation

These financial statements include the books of Biopulse International, Inc and its wholly owned subsidiary Biopulse, Inc. All intercompany transactions and balances
have been eliminated in the consolidation.

h. Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect
reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and expenses during the reporting period. In
these financial statements, assets, liabilities and expenses involve extensive reliance on management`s estimates. Actual results could differ from those estimates.

i. Accounts Receivable Allowance

BioPulse periodically reviews accounts receivable and the allowance for doubtful accounts. At October 31, 2000 the allowance was $8,435 and at October 31, 2001 the
allowance was $0, since there were no receivables at October 31, 2001.

F-6

Biopulse International, Inc.
Notes to the Financial Statements
October 31, 2001 and October 31, 2000

NOTE 1 - Summary of Significant Accounting Policies (continued)

j. Inventory

Inventory is recorded at the lower of cost or market on the first-in, first-out basis, and consists primarily of medicine, medical supplies and nutritional supplements.

Direct operating costs consist of direct costs incurred in the providing of care to patients. These costs include the cost of medicine, medical supplies, nutritional
supplements, laboratory fees, patient hotel rooms, patient meals and other direct costs. The salaries of in-house doctors and nurses are included in general and
administrative costs.

k. International Exchange

All fees are charged in U. S. dollars and most expenses are paid in U. S. dollars. Expenses that are paid in a foreign currency are converted into U. S. dollars at the
exchange rate in effect on the date of the transaction.

l. Research and Development Costs

As an integral part of its patient treatment operations, BioPulse conducts research designed to evaluate the effectiveness of patient treatment. All costs associated with
the patient`s care are expensed in the period that they are incurred. During the year ended July 31,2001, the company licensed TK-1 diagnostic technology from Brigham
Young University. It paid a non refundable fee of $100,000 for right to license this technology. This fee has been expensed as research and development costs along with
the cost the company has paid third party laboratories to develop this technology into a marketable product.

NOTE 2 - Property and Equipment

BioPulse capitalizes purchases of equipment with a useful life of more than one year. BioPulse also capitalizes improvements and costs that increases the value of or
extend the life of an asset.

Capitalized assets are depreciated over the estimated useful lives of the assets (five to seven years for furniture and fixtures and leasehold improvements, three to five
years for autos, medical and computer equipment) on the straight line basis.

F-7

Biopulse International, Inc.
Notes to the Financial Statements
October 31, 2001 and October 31, 2000

October 31, October 31,
2001 2000
----------- -----------
Property and Equipment consists of the following:
Furniture & Equipment $ 172,031 $ 171,301
Medical Equipment 676,497 683,104
Lab Equipment 209,061 --
Leasehold improvements 437,416 93,576
Auto 4,000 --
Accumulated Depreciation (263,982) (103,743)
----------- -----------
Total Property & Equipment $ 1,235,023 $ 848,238
=========== ===========




NOTE 2 - Property and Equipment (continued)

Depreciation expense was $ 46,116 and $31,850 for the three months ended October 31, 2001 and 2000, respectively.

NOTE 3 - Intangible Assets

BioPulse capitalized as intangible assets the purchase cost of the rights to certain technologies acquired from Aidan Inc. in August 2000. These assets are amortized over
their estimated useful life or the life of related patents whichever is shorter. BioPulse does not expect the technology to become obsolete during the 17 year useful life of
the patents. The technology and licenses acquired cover the world except for experimental use in the United States.

Intangible assets consist of the following at October 31, 2001:

Intangible Assets $ 700,000
Accumulated Amortization (62,500)
---------
Total Intangible Assets $ 637,500
=========




Amortization expense was $12,500 for the quarter ended October 31, 2001.

NOTE 4 - Equity/Reverse stock split

In November 1998, the board of directors authorized a 1 for 400 reverse stock split. These statements have been retroactively restated to reflect this reverse split.

During the year ended July 31, 1999, BioPulse issued the following:

- 4,000,000 shares of common stock for 100 percent of the outstanding stock of Biopulse, Inc. valued at $4,000.

- 2,000,000 shares of common stock for subscriptions receivable of $970,000.

F-8

Biopulse International, Inc.
Notes to the Financial Statements
October 31, 2001 and October 31, 2000

- 25,000 shares of preferred stock, class "A" for cash of $25,000.

- 25,374 shares of preferred stock, class "A" for services valued at $25,374. Cost of these services was recorded as general and administrative costs.

NOTE 4 - Equity/Reverse stock split (continued)

During the year ended July 31, 2000 BioPulse had issued the following:

- 600,000 shares to the underwriter for services rendered in the offering.

- 600,000 shares at $.10 per share pursuant to a subscription agreement.

- 5,000 shares for $3 per share.

During the year ended July 31, 2001 BioPulse issued the following:

- 35,000 shares of common stock for cash at $3 per share.

- 60,000 shares of common stock for equipment valued at $60,000
($1 per share.)

- 2,353,636 shares of common stock for cash at $0.41 per share.
In addition warrants were attached to these shares to purchase 189,000 shares of common stock. The exercise price shall be fifty percent of the lesser of: 1) $6.375 or
2) the average closing price for the five trading days immediately preceding the effective date of a registration statement covering these warrants.

- 1,050,000 shares of common stock pursuant to consulting with Liviakis Financial Communications (LFC) for investor relations services for one year valued at
$2,961,000 ($2.82 per share, the fair market value on the date the contract was signed). The shares were non- assessable upon signing on November 2, 2000. In addition,
the contract provides for cash commissions to LFC of 2.5% of the value of debt or equity financing and 2% of the value of the merger or acquisition for which LFC has
acted as a finder. This contract has been terminated.

- 80,000 shares were issued to three individuals for services valued at $679,370. The cost of these services will be recorded as general and administrative costs during
the quarter ended January 31, 2001.

F-9

Biopulse International, Inc.
Notes to the Financial Statements
October 31, 2001 and October 31, 2000

Options:

- At August 3, 2000 the company issued 1,500,000 options to purchase common stock at $2.75 (market price) to Aiden, Inc. in partial consideration for technology rights.
The shares are exercisable as follows:

- 700,000 immediately,

NOTE 4 - Equity/Reverse stock split (continued)

- 200,000 upon submission of patent application for production of tissue vaccine,

- 200,000 upon submission of patent application for MPGC,

- 200,000 upon submission of patent application for Cytokines,

- 200,000 upon submission of patent application for Tissue Vaccine.

The above options expire August 3, 2005.

The company has issued to Hunts Drive Ltd. in connection with the issuance of preferred stock outstanding warrants to purchase up to 184,300 common shares with an
exercise price of $8.40 per share. These warrants were granted on January 24, 2001 and expire on January 24, 2006.

The company also issued to Hunts Drive, Ltd. in connection with the issuance of preferred stock warrants to purchase up to 150,000 common shares with an exercise
price of $8.53 per share. These warrants were granted on January 24, 2001 and expire on January 24,2006.

In January 2001, in connection with a private pl

[Bombenleger]

Hier eine Mail vom Chairman MR.Reid Jilek die ich heute
erhalten habe.

Hello X,

All of the money for the development of TK1 is in a secure escrow account.
Unfortunately, the contract research laboratory conducting the developmental
work has run into obstacles. They keep telling us that they will be
finished, for example: 2nd Quarter 2001, 3rd Quarter 2001, 4th Quarter 2001.
They have lost credibility, from predicting final results. I do not feel it
appropriate to put out press releases until we have real results and dates.
I hope you understand. Also our SEC filings, put out quarterly give a bit of
an update, on TK1 and other parts of BioPulse.

Best Regards,

Reid


Schade das sich hier im Board keiner für den Wert interessiert.
Sicherlich,es gab einige Probleme und auch unsinnige Gerüchte.Ich
halte aber die Verbindung mit der alternativen Medizin für
durchaus interessant.

[Aktientiger]

Ist Biopulse am Ende, oder warum geht der Kurs so in den Keller?
Allerdings wurde gestern und in den USA einigermaßen hohe Stückzahlen gehandelt?
Weiß jemande etwas über den Stand der Dinge bezüglich der Entwicklung des Test`s?

Für jede Antwort dankbar

[Bombenleger]

March 18, 2002

BIOPULSE INTERNATIONAL INC/ (BIOP.OB)

Quarterly Report (SEC form 10QSB)

ITEM 2 MANAGEMENTS DISCUSSION AND ANALYSIS

Management`s Discussion and Analysis

The following discussion contains comments about the financial condition of BioPulse International, Inc. for the Quarter Ended January 31, 2002.

Overview

From January 1999 we have managed Clinica BioPulso in Tijuana, Mexico, through a management contract with a physician licensed in Mexico. We were entitled to all
revenues and are responsible for all expenses of the clinic. More than 90% of our operating revenues and expenses and profits were generated by the Mexican
operations.

During 2001, the Mexican government revamped its oversight of medical clinics subject to its jurisdiction. It sent new health department inspectors to review the
operations and permits of many clinics in Tijuana, Mexico. This led to the closure of several clinics there. Clinica BioPulso also was inspected. The inspectors
determined that while the clinic personnel were properly qualified, they had not submitted all of their protocols for government review. On February 15, 2001, one
treatment room was closed pending review of the protocols. The clinic submitted applications for licenses for four protocols (insulin hypoglycemic therapy, chelation,
colonic treatments, and dendrytic cell therapies) in May 2001. On May 9, 2001, the Instituto de Servicios de Salud Publica Del Estado De Baja California (the Mexican
health authorities) reopened the treatment room. As a result of the new policy, the clinic decided not to seek new cancer patients until all the necessary protocols had
been approved. In January 2002 management closed the clinic because the timing of the approval of the permits was uncertain and it was there were no longer funds
available to keep the clinic open.

Prior acquiring TK-1 technology in December, 2000, we have not incurred material research and development expenses outside of the treatment of patients at the clinic
in Tijuana, Mexico. We conducted research and development using data from records of the patients treated at the clinic in Mexico to determine the effectiveness of the
treatments. Additionally, we are working with the doctors who are modifying the treatments based on the data received from the treatment of patients. This limited
research and development has been integrated into the patient care given to paying patients, and we have not had any material research and development costs to date
that were distinguishable from patient care. All costs of patient care have been expensed in the period in which they were incurred. We paid $100,000 for the TK-1
technology that is not refundable should we not be able to develop a marketable product. This $100,000 has been expenses as research and development expenses plus
the costs incurred to develop TK-1 into a marketable product.

During 2000, we had an outpatient clinic at our office in Utah. The revenues and expenses generated by this clinic were not material, and the clinic no longer has any
ongoing patient care operations.

Revenues

The clinic produced almost no revenue during the quarter ended and six months ended January 31, 2002, down from $ 703,241 and 1,862,921 from clinic operations for
same period last year. This is due to our not accepting new cancer patients after being informed that we need additional permits from the Mexican government to offer
the treatments that had bee previously offered as discussed above.

Costs and Expenses

Cost of sales was $4,773 for the quarter and six months ended January 31, 2002 down from $ 298,137 and $ 696,496 from the same period last year. This is due to the
almost total loss of patients at the clinic. General and Administrative expenses were $ 466,057 and $ 1,094657 for the quarter and six months ended January 31, 2002
down from $ 5,481,987 and $6,161,790 for the same period last year. Most of the general and administrative expenses for the prior year were for the value of stock
issued for services. Most general and administrative expenses have been eliminated as of January 2002 due to the closing of the clinic in Tijuana Mexico.

Liquidity

As of January 31, 2002, the Company very little cash and is
looking to sell its clinic equipment and sublicense some of its intellectual
property. Most of the employees of Biopulse have been laid off and the remaining
two employees are working for deferred salaries. These salaries are accrued as a
liability on the financial statements. There are talks with a potential buyer of
the equipment and licensee of the TK-1 technology that if the sale is completed
would be sufficient to pay the accounts payable and accrued expenses. As of
October 1, 2001 we are in default on our loan of $500,000 with Hunts Drive Ltd.
That loan was secured by the 2,093,400 shares of stock owned by Loran Swensen
and Johathan Neville, Officers and Directors of the company.

Seasonal Aspects

None

Material Commitments for Capital Expenditures and Capital Resources

There are no material commitments for capital expenditures. BioPulse has committed to develop the ELISA kit for the TK-1 diagnostic technology that was acquired
from Brigham Young University. This is expected to cost less than $50,000.

[Aktientiger]

@Bombenleger,
Heißt soviel wie "Aus die MAus", oder?

Will Biopulse den Krebstest garnicht weiterentwickeln, sondern die Lizenz entwickeln?

[Aktientiger]

Sind bei Biopulse endgültig die Licher ausgegangen, oder gibt es noch Hoffnung für den Test?

Gehandelt werden die Shares ja noch, wenn auch in dürftigen Stückzahlen.


Gruß

[Bombenleger]

June 14, 2002

BIOPULSE INTERNATIONAL INC/ (BIOP.OB)

Quarterly Report (SEC form 10QSB)

ITEM 2 MANAGEMENT`S DISCUSSION AND ANALYSIS

Management`s Discussion and Analysis

The following discussion contains comments about the financial condition of BioPulse International, Inc. for the Quarter Ended April 30, 2002.

Overview

From January 1999 we have managed Clinica BioPulso in Tijuana, Mexico, through a management contract with a physician licensed in Mexico. We were entitled to
all revenues and are responsible for all expenses of the clinic. More than 90% of our operating revenues and expenses and profits were generated by the Mexican
operations.

During 2001, the Mexican government revamped its oversight of medical clinics subject to its jurisdiction. It sent new health department inspectors to review the
operations and permits of many clinics in Tijuana, Mexico. This led to the closure of several clinics there. Clinica BioPulso also was inspected. The inspectors
determined that while the clinic personnel were properly qualified, they had not submitted all of their protocols for government review. On February 15, 2001, one
treatment room was closed pending review of the protocols. The clinic submitted applications for licenses for four protocols (insulin hypoglycemic therapy, chelation,
colonic treatments, and dendrytic cell therapies) in May 2001. On May 9, 2001, the Instituto de Servicios de Salud Publica Del Estado De Baja California (the
Mexican health authorities) reopened the treatment room. As a result of the new policy, the clinic decided not to seek new cancer patients until all the necessary
protocols had been approved. In January 2002 management closed the clinic because the timing of the approval of the permits was uncertain and it was there were
no longer funds available to keep the clinic open.

Prior acquiring TK-1 technology in December, 2000, we have not incurred material research and development expenses outside of the treatment of patients at the
clinic in Tijuana, Mexico. We conducted research and development using data from records of the patients treated at the clinic in Mexico to determine the
effectiveness of the treatments. Additionally, we are working with the doctors who are modifying the treatments based on the data received from the treatment of
patients. This limited research and development has been integrated into the patient care given to paying patients, and we have not had any material research and
development costs to date that were distinguishable from patient care. All costs of patient care have been expensed in the period in which they were incurred. We
paid $100,000 for the TK-1 technology that is not refundable should we not be able to develop a marketable product. This $100,000 has been expensed as
research and development expenses plus the costs incurred to develop TK-1 into a marketable product.

During 2000, we had an outpatient clinic at our office in Utah. The revenues and expenses generated by this clinic were not material, and the clinic no longer has any
ongoing patient care operations.

Revenues

The clinic produced almost no revenue during the quarter ended and six months ended April 30, 2002, down from $ 285,360 and $ 2,128,281 from clinic
operations for same period last year. This is due to our not accepting new cancer patients after being informed that we need additional permits from the Mexican
government to offer the treatments that had bee previously offered as discussed above.

Costs and Expenses

Cost of sales was $4,773 for the and nine months ended April 30, 2002 down from $ 117,682 and $ 814,178 from the same period last year. This is due to the
almost total loss of patients at the clinic. General and Administrative expenses were $ 86,301 and $ 1,453,792 for the quarter and nine months ended April 30,
2002 down from $ 1,153,958 and $ 7,615,582 for the same period last year. Most of the general and administrative expenses for the prior year were for the value
of stock issued for services. Most general and administrative expenses have been eliminated as of January 2002 due to the closing of the clinic in Tijuana Mexico.

Liquidity -

As of April 30, 2002, the Company has very little cash and is looking to sell its clinic equipment and sublicense some of its intellectual property. The clinic has a
potential buyer for the clinic and to sublicense TK-1 technology in Europe. Most of the employees of Biopulse have been laid off and the remaining two employees
are working for deferred salaries. These salaries are accrued as a liability on the financial statements. There are talks with a potential buyer of the equipment and
licensee of the TK-1 technology that if the sale is completed would be sufficient to pay the accounts payable and accrued expenses. As of October 1, 2001 we are
in default on our loan of $500,000 with Hunts Drive Ltd. That loan was secured by the 2,093,400 shares of stock owned by Loran Swensen and Jonathan Neville,
Officers and Directors of the company.

Seasonal Aspects

None

Material Commitments for Capital Expenditures and Capital Resources -

There are no material commitments for capital expenditures. BioPulse has committed to develop the ELISA kit for the TK-1 diagnostic technology that was acquired
from Brigham Young University. This is expected to cost less than $50,000.

[Bombenleger]

BIOP Sees Q3 2002 Revenues Fall, Cuts Losses

Ridgeland, MS, JUN 14, 2002 (EventX/Knobias.com via COMTEX) -- BioPulse International Inc (OTCBB: BIOP) filed its
10QSB today, for the three months ended 4/30/2002.

BIOP reported Revenues of $1,250 for Q3 2002 vs. Revenues of $265,360 in Q3 2001.

BIOP posted a Net Loss of $(85,051) for Q3 2002 vs. a Net Loss of $(1,306,114) in Q3 2001.

As of 4/30/2002, the Company had a Working Capital Deficit of $(1,372,531) and an Accumulated Deficit of $(8,806,491).

GET KNOBIAS IN REAL-TIME: Delivery of this proprietary Knobias alert has been delayed by 10 minutes. To get all
Knobias alerts in real-time daily, visit http://www.knobias.com/cmtx

ABOUT KNOBIAS: Knobias is a financial information provider serving retail investors and trading professionals. Knobias
collects and maintains real-time and historical market intelligence on all U.S. securities, with special emphasis on
Over-the-Counter (OTC) stocks. Knobias provides customers with two core products: 1. Knobias FUNDAMENTALS: A
comprehensive web-based database of fundamental research covering thousands of U.S. securities; 2. Knobias RAiDAR: A
web-based desktop application that delivers thousands of real-time, intraday alerts daily. RAiDAR alerts include real-time
news, filings, trading alerts, earnings alerts, coverage alerts and critical corp actions.

KNOBIAS DISCLAIMER: Knobias has received no compensation from the Company or Companies mentioned in this story.
Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities
mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be
liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is
expressly prohibited without prior written consent of Knobias.com, LLC.

CONTACT: Knobias.com, LLC
601-978-3399
601-978-3675
[e-mail]
www.knobias.com/cmtx


Copyright 2002 Knobias.com, LLC, All rights reserved.

[steigenderengel]

HALLO GIB MAL BITTE DIE WKN : DANKE

[Bombenleger]

@ Steigenderengel

WKN 917016

[TheCooleWickerl]

servus

hab ich mich ein wenig mit BIOPULSE eingedeckt
jetzt glaube ich meinen augen nicht zu trauen
+ 1.900,00% in deutschland
sicherlich ein tippfehler?

die + 83,33% sind da wohl realer?

wickerl

[Aktientiger]

@theCooleWickerl,

gibt`s für Dich einen Grund bei Biopulse einzusteigen?
Bei dem Kurs?

Gruß

Aktientiger

P.S. ich halte meine Stücke in der waghalsigen Hoffung, dass der Test noch eine finanziellen Sponsor findet.

[Bombenleger]

California companies settle federal charges alleging they sold unproven cancer treatments

WASHINGTON, Jul 24, 2002 (AP WorldStream via COMTEX) -- Two California companies that touted insulin injections
and "acoustic lightwave therapy" as cancer treatments have settled federal charges that they lacked proof their methods
worked and were safe.

BioPulse International Inc. and BioPulse Inc., based in San Ysidro near the Mexican border, are now barred from making
unsupported claims or misrepresenting the safety of treatments, the Federal Trade Commission said Wednesday. The
companies treat patients at a Tijuana, Mexico clinic.

The settlement also contains a suspended fine of dlrs 4.3 million, which is due in full if the companies are found to have
misrepresented their ability to pay, the FTC said. By settling, the companies do not admit to breaking any law.

Calls to the companies and their officers seeking comment were not immediately returned Wednesday.

The FTC`s complaint said the companies marketed two "alternative" therapies to treat numerous serious diseases, including
cancer.

According to the government complaint, one BioPulse ad said: "At the BioPulse clinic in Tijuana, patients have seen tumors
decrease substantially or even disappear from the brain, lung, bone, prostate, liver and breast."

BioPulse`s "insulin-induced hypoglycemic sleep therapy" involved injecting insulin into cancer patients to starve cancer tumors
and "cleanse the body through sweating," the FTC said. A seven-week treatment cost up to dlrs 39,900.

The acoustic lightwave therapy allegedly worked by shining special lights on patients to destroy cells or organisms that caused
arthritis, diabetes, flu, headaches, parasites, lyme disease, pneumonia, and some cancers.

"We asked them to substantiate their claims, to show us these therapies worked and they didn`t give us sufficient proof," said
Laura Fremont, an FTC attorney.

The FTC said the company allegedly also made unsupported safety claims about the insulin therapy.

The complaint and proposed settlement were filed Tuesday in the U.S. District Court for the Northern District of California.

---

On the Net:

FTC: http://www.ftc.gov

By DAVID HO Associated Press Writer

Copyright 2002 Associated Press, All rights reserved